Related Experiment Video
Updated: Apr 7, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance
Kideok Jin1, Sunju Park1, Wei Wen Teo1
1Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Unlabelled:
Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor-α (ERα) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 chromatin immunoprecipitation analysis followed by validation showed that HOXB7 physically interacts with ERα, and that the HOXB7-ERα complex enhances transcription of many ERα target genes, including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR-HER2 signaling, inhibits transcription of miR-196a, a HOXB7 repressor. This leads to increased expression of HOXB7, ER target genes, and HER2. Repressing MYC using small-molecule inhibitors reverses these events and causes regression of breast cancer xenografts. The MYC-HOXB7-HER2 signaling pathway is eminently targetable in endocrine-resistant breast cancer.
Significance:
HOXB7 acts as an ERα cofactor regulating a myriad of ER target genes, including HER2, in tamoxifen-resistant breast cancer. HOXB7 expression is controlled by MYC via transcriptional regulation of the HOXB7 repressor miR-196a; consequently, antagonists of MYC cause reversal of selective ER modulator resistance both in vitro and in vivo.
Insights
The study reveals that the MYC-HOXB7-HER2 pathway drives tamoxifen resistance in breast cancer. Targeting MYC reverses this resistance and shrinks tumors, offering a new therapeutic strategy for endocrine-resistant breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tamoxifen resistance in estrogen receptor-α (ERα)-positive breast cancer remains a clinical challenge.
- The mechanisms underlying resistance and high HER2 expression are not fully understood.
Purpose of the Study:
- To elucidate the role of HOXB7 in tamoxifen resistance and HER2 overexpression.
- To identify regulatory factors controlling HOXB7 expression.
- To explore therapeutic strategies targeting this pathway.
Main Methods:
- Chromatin immunoprecipitation assays to assess HOXB7-ERα interaction.
- Analysis of gene transcription and protein expression.
- In vitro and in vivo studies using small-molecule inhibitors of MYC.
Main Results:
- HOXB7 acts as a cofactor for ERα, enhancing transcription of ER target genes, including HER2.
- MYC stabilizes itself through EGFR-HER2 signaling, inhibiting miR-196a (a HOXB7 repressor).
- Increased HOXB7 leads to elevated ER target genes and HER2 expression, driving tamoxifen resistance.
- Repressing MYC reversed resistance and caused breast cancer xenograft regression.
Conclusions:
- HOXB7 is a key ERα cofactor in tamoxifen-resistant breast cancer, regulating HER2 expression.
- The MYC-miR-196a axis controls HOXB7 levels.
- MYC antagonists effectively reverse endocrine resistance in vitro and in vivo.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Regulation of Angiogenesis and Blood Supply
Hedgehog Signaling Pathway
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Master Transcription Regulators
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...

